Ciglitazone
Ciglitazone structure
|
Common Name | Ciglitazone | ||
|---|---|---|---|---|
| CAS Number | 74772-77-3 | Molecular Weight | 333.445 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 504.5±23.0 °C at 760 mmHg | |
| Molecular Formula | C18H23NO3S | Melting Point | 130-131ºC | |
| MSDS | Chinese USA | Flash Point | 258.9±22.6 °C | |
Use of CiglitazoneCiglitazone is a potent and selective PPARγ agonist (EC50=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells[1][2][3][4]. |
| Name | ciglitazone |
|---|---|
| Synonym | More Synonyms |
| Description | Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells[1][2][3][4]. |
|---|---|
| Related Catalog | |
| In Vitro | Ciglitazone (0-20 μM; 24 hours) induces apoptosis through PPAR-independent mechanism. Ciglitazone causes generation of ROS and an increase in intracellular Ca2+[4]. |
| In Vivo | In C57BL/6J-ob/ob mice, Ciglitazone (100 mg/kg/day; 2 days) elicits a drastic fall in blood glucose. Regranulation of islet beta-cells and increased pancreatic insulin content are observed in ob/ob mice treated for 41-44 days with 100 mg/kg/day Ciglitazone[3]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 504.5±23.0 °C at 760 mmHg |
| Melting Point | 130-131ºC |
| Molecular Formula | C18H23NO3S |
| Molecular Weight | 333.445 |
| Flash Point | 258.9±22.6 °C |
| Exact Mass | 333.139862 |
| PSA | 80.70000 |
| LogP | 4.69 |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.568 |
| Storage condition | 2-8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;half-mask respirator (US);multi-purpose combination respirator cartridge (US) |
|---|---|
| Hazard Codes | Xn |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | XJ5813700 |
|
Developmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumors.
PLoS ONE 10(4) , e0122820, (2015) Cytochrome P450 2W1 (CYP2W1) is expressed predominantly in colorectal and also in hepatic tumors, whereas the levels are insignificant in the corresponding normal human adult tissues. CYP2W1 has been ... |
|
|
Autonomous inhibition of apoptosis correlates with responsiveness of colon carcinoma cell lines to ciglitazone.
PLoS ONE 9(12) , e114158, (2014) Colorectal cancer is a leading cause of mortality worldwide. Resistance to therapy is common and often results in patients succumbing to the disease. The mechanisms of resistance are poorly understood... |
|
|
Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery.
J. Gen. Physiol. 138(2) , 249-70, (2011) The thiazolidinediones (TZDs) are used in the treatment of diabetes mellitus type 2. Their canonical effects are mediated by activation of the peroxisome proliferator-activated receptor γ (PPARγ) tran... |
| Ciglitazone |
| UNII:U8QXS1WU8G |
| ciglitazonum |
| 2,4-Thiazolidinedione, 5-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]- |
| CIGLITIZONE |
| CIGLITLZONE |
| MFCD00865499 |
| 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4-dione |
| Flurofamide |
| AD-4533 |
| ciglitazona |
| ADD 3878 |
| 5-{4-[(1-Methylcyclohexyl)methoxy]benzyl}-1,3-thiazolidine-2,4-dione |
| Ciglitazone,5-[[4-[(1-Methylcyclohexyl)methoxy]phenyl]methyl]-2,4-thiazolidinedione |